Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors

Propanc Biopharma, Inc. announced the successful production of synthetic recombinant proenzymes trypsinogen and chymotrypsinogen through the Proenzyme Optimization Project 1 (POP1) joint research and drug discovery program. The project was conducted in collaboration with the Universities of Jaén and Granada, Spain. The synthetic development of these proenzymes aims to create a backup clinical co..

• format_list_bulleted Pharmacology/BS
• · 2023. 7. 6.
• textsms

Propanc Biopharma Provides Shareholder Update and Plans to Enter Clinical Development Stage with Lead Cancer Treatment Candidate

Propanc Biopharma, a biopharmaceutical company focused on developing novel cancer treatments for patients with recurring and metastatic cancer, has announced that it is entering into a transformational stage as it prepares to file a Form 10-K annual report. The report will include recent developments and forecast for 2023/24. Propanc's lead product candidate PRP targets and eradicates cancer ste..

• format_list_bulleted Pharmacology/BS
• · 2023. 6. 23.
• textsms